Literature DB >> 18697213

Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin.

Juliane Karthe1, Kathi Tessmann, Jisu Li, Raiki Machida, Maaike Daleman, Dieter Häussinger, Tobias Heintges.   

Abstract

The hepatitis C virus (HCV) core protein is essential for viral genome encapsidation and plays an important role in steatosis, immune evasion, and hepatocellular carcinoma. It may thus represent a promising therapeutic target to interfere with the HCV life-cycle and related pathogenesis. In this study, we used phage display to generate single-chain variable domain antibody fragments (scFv) to the core protein from bone marrow plasma cells of patients with chronic hepatitis C. An antibody with high-affinity binding (scFv42C) was thus identified, and the binding site was mapped to the PLXG motif (residues 84-87) of the core protein conserved among different genotypes. Whereas scFv42C displayed diffuse cytoplasmic fluorescence when expressed alone in the Huh7 human hepatoma cell line, cotransfection with the core gene shifted its subcellular distribution into that of core protein. The intracellular association of scFv42C with its target core protein was independently demonstrated by the fluorescence resonance energy transfer technique. Interestingly, expression of the single-chain antibody reduced core protein levels intracellularly, particularly in the context of full HCV replication. Moreover, cell proliferation as induced by the core protein could be reversed by scFv4C coexpression. Therefore, scFv42C may represent a novel anti-HCV agent, which acts by sequestering core protein and attenuating core protein-mediated pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697213      PMCID: PMC3080105          DOI: 10.1002/hep.22366

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  42 in total

1.  The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line.

Authors:  C S Hahn; Y G Cho; B S Kang; I M Lester; Y S Hahn
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

2.  Phage antibodies: filamentous phage displaying antibody variable domains.

Authors:  J McCafferty; A D Griffiths; G Winter; D J Chiswell
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

3.  A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.

Authors:  R D Alvarez; M N Barnes; J Gomez-Navarro; M Wang; T V Strong; W Arafat; R B Arani; M R Johnson; B L Roberts; G P Siegal; D T Curiel
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

4.  Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation.

Authors:  D Y Jin; H L Wang; Y Zhou; A C Chun; K V Kibler; Y D Hou; H Kung; K T Jeang
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

5.  Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment.

Authors:  D Jean; C Tellez; S Huang; D W Davis; C J Bruns; D J McConkey; S H Hinrichs; M Bar-Eli
Journal:  Oncogene       Date:  2000-05-18       Impact factor: 9.867

Review 6.  Recombinant antibodies for cancer diagnosis and therapy.

Authors:  Christelle Souriau; Peter J Hudson
Journal:  Expert Opin Biol Ther       Date:  2003-04       Impact factor: 4.388

7.  Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR.

Authors:  Xue-Bing Yan; Serena Battaglia; Delphine Boucreux; Zhi Chen; Christian Brechot; Nicole Pavio
Journal:  Virus Res       Date:  2007-01-30       Impact factor: 3.303

8.  Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif.

Authors:  Björn Schwer; Shaotang Ren; Thomas Pietschmann; Jürgen Kartenbeck; Katrin Kaehlcke; Ralf Bartenschlager; T S Benedict Yen; Melanie Ott
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

9.  Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies.

Authors:  Olga Artsaenko; Kathi Tessmann; Markus Sack; Dieter Häussinger; Tobias Heintges
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

10.  Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs.

Authors:  Krister Melén; Riku Fagerlund; Maria Nyqvist; Päivi Keskinen; Ilkka Julkunen
Journal:  J Med Virol       Date:  2004-08       Impact factor: 2.327

View more
  4 in total

1.  Phages harboring specific peptides that recognize the N protein of the porcine reproductive and respiratory syndrome virus distinguish the virus from other viruses.

Authors:  Xiaofeng Ren; Mingcui Wang; Jiechao Yin; Guangxing Li
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

2.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

Review 3.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

4.  The protective effect of a combination of human intracellular and extracellular antibodies against the highly pathogenic avian influenza H5N1 virus.

Authors:  Qiu Jin; Zhangyu Yao; Fangzhou Liu; Yaxuan Di; Jun Gao; Xiao Zhang
Journal:  Hum Vaccin Immunother       Date:  2022-03-03       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.